Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • OptimizeRx's Depreciation & Amortization (CF) fell 136.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 235.74%. This contributed to the annual value of $4.3 million for FY2024, which is 8022.48% up from last year.
  • Per OptimizeRx's latest filing, its Depreciation & Amortization (CF) stood at $1.1 million for Q3 2025, which was down 136.99% from $1.1 million recorded in Q2 2025.
  • OptimizeRx's 5-year Depreciation & Amortization (CF) high stood at $1.1 million for Q3 2024, and its period low was $385152.0 during Q4 2021.
  • Over the past 5 years, OptimizeRx's median Depreciation & Amortization (CF) value was $578116.0 (recorded in 2022), while the average stood at $759600.9.
  • Per our database at Business Quant, OptimizeRx's Depreciation & Amortization (CF) plummeted by 1956.63% in 2023 and then surged by 13447.54% in 2024.
  • OptimizeRx's Depreciation & Amortization (CF) (Quarter) stood at $385152.0 in 2021, then rose by 18.54% to $456545.0 in 2022, then skyrocketed by 120.57% to $1.0 million in 2023, then increased by 8.64% to $1.1 million in 2024, then dropped by 1.28% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.